Confronto
Leuprorelin vs. Linaclotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
53714-56-0
851199-59-2
Peso molecolare
1209.4 g/mol
1526.74 g/mol
Emivita
3 h
nessun dato
Sequenza
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtnessun dato
Meccanismo d'azione
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
0
di cui sull'uomo
4
0
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
3
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Leuprorelin and Linaclotid?
- Leuprorelin is classified as "Ricerca (altro)", while Linaclotid is classified as "Ricerca (altro)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Linaclotid?
- The highest available evidence level is "RCT sull'uomo" for Leuprorelin and "RCT sull'uomo" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Linaclotid in Germany and the United States?
- Germania: Leuprorelin — Su prescrizione, Linaclotid — Su prescrizione. Stati Uniti: Leuprorelin — Su prescrizione, Linaclotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.